Summary
This document is an executive summary detailing a Joint Working project between GlaxoSmithKline (GSK) and NHS Norfolk and Waveney ICB focused on Chronic Obstructive Pulmonary Disease (COPD). The project aims to validate the COPD disease register in participating practices, ensuring that at-risk patients receive timely reviews based on established management guidelines. It outlines the financial contributions from both GSK and the NHS, including funding for patient reviews and resources allocated for project management. The intended benefits for patients include comprehensive COPD reviews, optimized management strategies, and improved healthcare experiences. Additionally, the summary describes the benefits for NHS, such as enhanced patient identification, consistent guideline implementation, and opportunities for healthcare professional upskilling. GSK's involvement is also highlighted, emphasizing the potential for increased collaboration and understanding of NHS challenges. The project is set to run from May 2023 to December 2023.
